Firategrast

DB12732InvestigationalSmall molecule

Firategrast has been used in trials studying the treatment of Multiple Sclerosis.

Mechanism: Pharmacologically active on Integrin alpha-4, Integrin beta-7, and VLA-4 (very late antigen-4)
Curator reviewed
Formula / weight: C₂₇H₂₇F₂NO₆ · 499.511 g/mol (avg)
Code names: SB-683699

Resolves to

Compound

Structure

InChIKeyYLFZHHDVRSYTKT-NRFANRHFSA-NSMILESCCOCC1=CC(OC)=C(C(OC)=C1)C1=CC=C(C[C@H](NC(=O)C2=C(F)C=CC=C2F)C(O)=O)C=C1

Targets

What you can answer from here — as of July 07, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Firategrast, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.